Literature DB >> 25318459

Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Wilma Neumann1, Brenda C Crews, Menyhárt B Sárosi, Cristina M Daniel, Kebreab Ghebreselasie, Matthias S Scholz, Lawrence J Marnett, Evamarie Hey-Hawkins.   

Abstract

Cyclooxygenase (COX) is an enzyme involved in tumorigenesis and is associated with tumor cell resistance against platinum-based antitumor drugs. Cisplatin analogues were conjugated with COX inhibitors (indomethacin, ibuprofen) to study the synergistic effects that were previously observed in combination treatments. The conjugates ensure concerted transport of both drugs into cells, and subsequent intracellular cleavage enables a dual-action mode. Whereas the platinum(II) complexes showed cytotoxicities similar to those of cisplatin, the platinum(IV) conjugates revealed highly increased cytotoxic activities and were able to completely overcome cisplatin-related resistance. Although some of the complexes are potent COX inhibitors, the conjugates appear to execute their cytotoxic action via COX-independent mechanisms. Instead, the increased lipophilicity and kinetic inertness of the conjugates seem to facilitate cellular accumulation of the platinum drugs and thus improve the efficacy of the antitumor agents. These conjugates are important tools for the elucidation of the direct influence of COX inhibitors on platinum-based anticancer drugs in tumor cells.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antitumor agents; cyclooxygenase inhibitors; drug design; platinum; prodrugs

Mesh:

Substances:

Year:  2014        PMID: 25318459      PMCID: PMC4480879          DOI: 10.1002/cmdc.201402353

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  84 in total

1.  Structure-activity relationship of P-glycoprotein substrates and modifiers.

Authors:  A Seelig; E Landwojtowicz
Journal:  Eur J Pharm Sci       Date:  2000-11       Impact factor: 4.384

2.  Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Authors:  Md Jashim Uddin; Brenda C Crews; Anna L Blobaum; Philip J Kingsley; D Lee Gorden; J Oliver McIntyre; Lynn M Matrisian; Kotha Subbaramaiah; Andrew J Dannenberg; David W Piston; Lawrence J Marnett
Journal:  Cancer Res       Date:  2010-05-01       Impact factor: 12.701

3.  Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth.

Authors:  K Hattori; R Matsushita; K Kimura; Y Abe; E Nakashima
Journal:  Biol Pharm Bull       Date:  2001-10       Impact factor: 2.233

4.  Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors.

Authors:  Stuart J Mercer; Federica Di Nicolantonio; Louise A Knight; Francis G Gabriel; Pauline A Whitehouse; Sanjay Sharma; Augusta Fernando; Pradeep Bhandari; Shaw S Somers; Simon K Toh; Ian A Cree
Journal:  Anticancer Drugs       Date:  2005-06       Impact factor: 2.248

5.  trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.

Authors:  Valentina Gandin; Cristina Marzano; Giorgio Pelosi; Mauro Ravera; Elisabetta Gabano; Domenico Osella
Journal:  ChemMedChem       Date:  2014-04-08       Impact factor: 3.466

Review 6.  Signalling networks regulating cyclooxygenase-2.

Authors:  Christos Tsatsanis; Ariadne Androulidaki; Maria Venihaki; Andrew N Margioris
Journal:  Int J Biochem Cell Biol       Date:  2006-04-25       Impact factor: 5.085

7.  Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Authors:  L R Kelland; G Abel; M J McKeage; M Jones; P M Goddard; M Valenti; B A Murrer; K R Harrap
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

Review 8.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Authors:  Alexander Greenhough; Helena J M Smartt; Amy E Moore; Heather R Roberts; Ann C Williams; Christos Paraskeva; Abderrahmane Kaidi
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

9.  Celecoxib activates a novel mitochondrial apoptosis signaling pathway.

Authors:  Verena Jendrossek; René Handrick; Claus Belka
Journal:  FASEB J       Date:  2003-06-17       Impact factor: 5.191

10.  Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination.

Authors:  Michael R Reithofer; Seied M Valiahdi; Michael A Jakupec; Vladimir B Arion; Alexander Egger; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2007-11-22       Impact factor: 7.446

View more
  14 in total

1.  Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.

Authors:  Md Jashim Uddin; Brenda C Crews; Shu Xu; Kebreab Ghebreselasie; Cristina K Daniel; Philip J Kingsley; Surajit Banerjee; Lawrence J Marnett
Journal:  ACS Chem Biol       Date:  2016-09-19       Impact factor: 5.100

2.  A Carrier-Free Nanostructure Based on Platinum(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity.

Authors:  Jingjie Tan; Chan Li; Qian Wang; Shuyi Li; Shizhu Chen; Jinchao Zhang; Paul C Wang; Lei Ren; Xing-Jie Liang
Journal:  Mol Pharm       Date:  2018-03-14       Impact factor: 4.939

3.  Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition.

Authors:  Lin Deng; Ding-Qing Feng; Bin Ling
Journal:  J Zhejiang Univ Sci B       Date:  2020 Apr.       Impact factor: 3.066

4.  Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.

Authors:  Idris Raji; Fatima Yadudu; Emily Janeira; Shaghayegh Fathi; Lindsey Szymczak; James Richard Kornacki; Kensei Komatsu; Jian-Dong Li; Milan Mrksich; Adegboyega K Oyelere
Journal:  Bioorg Med Chem       Date:  2016-12-24       Impact factor: 3.641

Review 5.  Pro-Inflammatory Signalling PRRopels Cisplatin-Induced Toxicity.

Authors:  Ivan K Domingo; Asna Latif; Amit P Bhavsar
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

Review 6.  The Platin-X series: activation, targeting, and delivery.

Authors:  Uttara Basu; Bhabatosh Banik; Ru Wen; Rakesh K Pathak; Shanta Dhar
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

Review 7.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

8.  Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.

Authors:  Dina Tolan; Valentina Gandin; Liam Morrison; Ahmed El-Nahas; Cristina Marzano; Diego Montagner; Andrea Erxleben
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

9.  Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin.

Authors:  Yulia N Nosova; Ilia V Zenin; Varvara P Maximova; Ekaterina M Zhidkova; Kirill I Kirsanov; Ekaterina A Lesovaya; Anna A Lobas; Mikhail V Gorshkov; Olga N Kovaleva; Elena R Milaeva; Markus Galanski; Bernhard K Keppler; Alexey A Nazarov
Journal:  Bioinorg Chem Appl       Date:  2017-07-19       Impact factor: 7.778

10.  Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance.

Authors:  Emanuele Petruzzella; Roman Sirota; Irene Solazzo; Valentina Gandin; Dan Gibson
Journal:  Chem Sci       Date:  2018-04-24       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.